Why Inventiva Shares Are Trading Higher By 24%; Here Are 20 Stocks Moving Premarket
Portfolio Pulse from Lisa Levin
Inventiva shares rose 24% in pre-market trading after announcing positive Phase II clinical trial results for lanifibranor in T2D and NAFLD patients. Other pre-market gainers include Cyxtera Technologies, WiSA Technologies, T2 Biosystems, and Oncorus. Pre-market losers include Eastside Distilling, Cineverse Corp, Medigus, Advanced Health Intelligence, and The OLB Group.
June 14, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inventiva shares gained 24% in pre-market trading after announcing positive Phase II clinical trial results for lanifibranor in T2D and NAFLD patients.
Inventiva's positive Phase II clinical trial results for lanifibranor in T2D and NAFLD patients indicate a potential breakthrough in treatment, which could lead to increased demand for the company's stock. This news is directly related to the company's core business and is likely to have a significant impact on its stock price in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100